Background A systematic review and meta-analysis was conducted to evaluate the efficacy and safety of macrolide therapy in adults and children with bronchiectasis. Methods We searched the PUBMED, EMBASE, CENTRAL databases to identify relevant studies. Two reviewers evaluated the studies and extracted data independently. The primary outcome was the number of bronchiectasis exacerbations. Secondary outcomes included exacerbation-related admissions, quality of life (QoL), spirometry, 6-minute walk test (6MWT) and adverse events. Results Nine eligible trials with 559 participants were included. Six were conducted on adults, and the remaining on children. Macrolide therapy significantly reduced the number of patients experiencing one or more exacerbation in adults [risk ratio (RR) = 0.59; 95% CI, 0.40 to 0.86; P = 0.006; I2 = 65%] and children [RR = 0.86; 95% CI, 0.75–0.99; P = 0.04; I2 = 0%], but not the number of patients with admissions for exacerbation. Macrolide therapy was also associated with reduced frequency of exacerbations in adults (RR = 0.42; 95% CI, 0.29 to 0.61; P<0.001; I2 = 64%) and children (RR = 0.50; 95% CI, 0.35 to 0.71; P<0.001). Pooled analyses suggested that spirometry, including FEV1 and FVC, were significantly improved in adults but not in children. Macrolide therapy improved the QoL (WMD, ？6.56; 95% CI, ？11.99 to ？1.12; P = 0.02; I2 = 86%) but no significant difference in 6MWT (WMD, 4.15; 95% CI, ？11.83 to 20.13; P = 0.61; I2 = 31%) and the overall adverse events (RR, 0.96; 95% CI, 0.82 to 1.13; P = 0.66; I2 = 0%) in adults. However, reports of diarrhea and abdominal discomforts were higher with macrolide therapy. Conclusions Macrolide maintenance therapy, both in adults and children, was effective and safe in reducing bronchiectasis exacerbations, but not the admissions for exacerbations. In addition, macrolide administration in adults was associated with improvement in QoL and spirometry, but not 6WMT. Future studies are warranted to verify the optimal populations and clarify its potential effects on antimicrobial resistance.
References
[1]
Pasteur MC, Bilton D, Hill AT (2010) British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65 (Suppl 1) i1–58. doi: 10.1136/thx.2010.136119
[2]
De Soyza A, Brown JS, Loebinger MR (2013) Research priorities in bronchiectasis. Thorax 68: 695–696. doi: 10.1136/thoraxjnl-2012-202893
[3]
Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte T, et al. (2013) Bronchiectasis-associated hospitalizations in Germany, 2005–2011: a population-based study of disease burden and trends. PLoS ONE 8: e71109. doi: 10.1371/journal.pone.0071109
[4]
Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, et al. (2010) Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006. Chest 138: 944–949. doi: 10.1378/chest.10-0099
[5]
Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R (2012) Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 142: 432–439. doi: 10.1378/chest.11-2209
[6]
Twiss J, Metcalfe R, Edwards E, Byrnes C (2005) New Zealand national incidence of bronchiectasis “too high” for a developed country. Arch Dis Child 90: 737–740. doi: 10.1136/adc.2004.066472
[7]
Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL (1997) Bronchiectasis in Finland: trends in hospital treatment. Respir Med 91: 395–398. doi: 10.1016/s0954-6111(97)90251-1
[8]
Cai Y, Chai D, Wang R, Bai N, Liang BB, et al. (2011) Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 66: 968–978. doi: 10.1093/jac/dkr040
[9]
Reiter J, Demirel N, Mendy A, Gasana J, Vieira ER, et al. (2013) Macrolides for the long-term management of asthma - a meta-analysis of randomized clinical trials. Allergy 68: 1040–1049. doi: 10.1111/all.12199
[10]
Spagnolo P, Fabbri LM, Bush A (2013) Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 42: 239–251. doi: 10.1183/09031936.00136712
[11]
Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M (1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157: 1829–1832. doi: 10.1164/ajrccm.157.6.9710075
[12]
Benden C, Boehler A (2009) Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 87: 1538–1540. doi: 10.1097/tp.0b013e3181a492b2
[13]
Yao GY, Ma YL, Zhang MQ, Gao ZC (2013) Macrolide Therapy Decreases Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis. Respiration Doi:10.1159/000350828 (Article in press).
[14]
Kanoh S, Rubin BK (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23: 590–615. doi: 10.1128/cmr.00078-09
[15]
Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, et al. (2013) Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 309 (12) 1260–1267. doi: 10.1001/jama.2013.2290
[16]
Altenburg J, Graaff CS, Stienstra Y, Sloos JH, Haren EH, et al. (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309 (12) 1251–1259. doi: 10.1001/jama.2013.1937
[17]
Wong C, Jayaram L, Karalus N, Eaton T, Tong C, et al. (2012) Azithromycin for prevention of exacerbations in non-cystic fi brosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. The Lancet 380: 660–667. doi: 10.1016/s0140-6736(12)60953-2
[18]
Evans DJ, Bara AI, Greenstone M (2007) Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev: CD001392.
[19]
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12. doi: 10.1016/0197-2456(95)00134-4
[20]
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558. doi: 10.1002/sim.1186
[21]
Koh YY, Lee MH, Sun YH, Sung KW, Chae JH (1997) Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 10 (5) 994–999. doi: 10.1183/09031936.97.10050994
[22]
Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, et al. (1999) A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 13: 361–364. doi: 10.1183/09031936.99.13236199
[23]
Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, et al. (2005) The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 4: 117–122. doi: 10.2165/00151829-200504020-00005
[24]
Masekela R, Anderson R, Gongxeka H, Steel HC, Becker PJ, et al. (2013) Lack of efficacy of an immunomodulatory macrolide in childhood HIV related bronchiectasis: A randomised, placebo-controlled trial. J Antivir Antiretrovir 5: 044–049. doi: 10.4172/jaa.1000062
[25]
de Diego A, Milara J, Martinez E, Palop M, Leon M, et al. (2013) Effects of Long-term Azithromycin Therapy on Airway Oxidative Stress Markers in non-Cystic Fibrosis bronchiectasis. Respirology Doi:10.1111/resp.12130. (Article in press).
[26]
Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, et al. (2013) Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 1: 610–620. doi: 10.1016/s2213-2600(13)70185-1
[27]
Poletti V, Casoni G, Chilosi M, Zompatori M (2006) Diffuse panbronchiolitis. Eur Respir J 28: 862–871. doi: 10.1183/09031936.06.00131805
[28]
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, et al. (2012) Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 186: 657–665. doi: 10.1164/rccm.201203-0487oc
[29]
Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, et al. (2004) Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 400–407. doi: 10.1164/rccm.200305-648oc
[30]
Jones PW (2005) St. George's Respiratory Questionnaire: MCID. COPD 2: 75–79. doi: 10.1081/copd-200050513
[31]
Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J (2007) Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132: 1565–1572. doi: 10.1378/chest.07-0490
[32]
Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R (1997) Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 156: 536–541. doi: 10.1164/ajrccm.156.2.9607083
[33]
Serisier DJ (2013) Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 1: 262–274. doi: 10.1016/s2213-2600(13)70038-9
[34]
Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366: 1881–1890. doi: 10.1056/nejmoa1003833
[35]
Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, et al. (2013) Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 346: f1235. doi: 10.1136/bmj.f1235
